Rocket Pharmaceuticals announces data from the Phase 1 clinical trial of RP A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy at ASGCT 2025

Rocket Pharmaceuticals a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA.

Details for the oral presentation of the abstract at ASGCT are as follows:

Title: Preliminary Data from a Phase I Gene Therapy Trial of RP-A601 (AAVrh.74-PKP2a) for Adult Patients with PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Session: Late-Breaking Abstracts I
Presenter: Barry H. Greenberg, MD, FHFSA, Distinguished Professor of Medicine at University of California San Diego School of Medicine and Director of the Advanced Heart Failure Treatment Program at UC San Diego Health
Date and Time: Thursday, May 15, from 2:00-2:15 p.m. CT

Rocket plans to host an investor webinar on May 15, 2025, at 4:30 p.m. ET. To join the investor webinar, please register at https://www.webcaster4.com/Webcast/Page/3046/52359. Webinar details will be posted on the Events and Presentations page of the Rocket website at www.RocketPharma.com.